About Us

Orgamedi seeks to
become an international
company by 2020. This is
what we stand for.

Orgamedi is a company that has secured advanced technology with years of preliminary basic research through joint research with, Yonsei University Medical Center, which boasts 130 years of history and tradition. Launched in 2016, Orgamedi has acquired the technology that uses flexible filament materials to produce custom human organs. Our 3D printed anatomical parts, overcomes the limits of x-rays, CT scans, and MRIs. With the purpose to aid physicians around the world, Orgamedi's 3D models are intricately designed and produced. Instead of coloring the surface of a mono-color print, Orgamedi's models are printed with full color filaments which increases similarity with actual organs. Therefore, we have achieved world-class competitiveness by launching the first flexible color products in Korea.

One of Orgamedi's revolutionary findings was developing a scaffold field not available in Korea, which is necessary for basic medical experiments. We succeeded in achieving 50μm fiber space, which is 6 times higher than conventional 300μm precision.

The biggest driving force behind these successes is our people, the talents of Orgamedi. Orgamedi develops specialized products and technologies with engineers of specialized skills and medical research teams at Severance Hospital. It is our strong corporate culture that keeps our principles professionally and humbly competitive and challenging. On the basis of that, we strive to provide satisfaction to doctors and patients and will advance the idea of a 'Globalized Orgamedi'

We are leaping vigorously towards 'Global Orgamedi'. As you can see from the National Institutes of Health's database, there are more than 3,000 medical 3D printing researches. Proving the fact that there are many applications in the world regarding 3D techonology. In addition, the future development of Orgamedi's technology will benefit cancer treatment with the manufacturing technology of shape memory polymer by 2020.

At Orgamedi, our objective is to contribute to the improvement of the quality of human health and medical care with our innovative technology, Severance medical researchers, and Orgamedi staff, all over the world.
Orgamedi will continue to innovate and challenge current limitations to achieve our vision.

Orgamedi CEO David Kwon